BRUIN CLL-314 is the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve patients INDIANAPOLIS, July 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: ...
Eilean Therapeutics is a biopharmaceutical company focused on the development of best-in-class and first-in-class small molecule inhibitors that target escape mutations in hematologic malignancies and ...
In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine ...
At ASH 2025, sonrotoclax demonstrated encouraging response rates and a favorable safety profile as a single-agent BCL2 ...
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has approved MYQORZO™ (aficamten), 5 mg, 10 mg, 15 mg, 20 mg tablets for the treatment of ...
MADISON, Wis.--(BUSINESS WIRE)--Research published in Science reveals a new target for non-hormonal male contraception. The protein, a kinase called STK33, has been linked to infertility in male mice ...
Pirtobrutinib met the primary endpoint of response rate non-inferiority, favoring pirtobrutinib with a nominal P-value for superiority < 0.05 Progression-free survival data was immature, but trending ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback